Premium
Induction of differentiation in U‐937 and NB4 cells is associated with inhibition of tissue factor production
Author(s) -
Tenno Taavo,
Öberg Fredrik,
Nilsson Kenneth,
Siegbahn Agneta
Publication year - 1999
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1999.tb01124.x
Subject(s) - haematopoiesis , retinoic acid , monocyte , tissue factor , cellular differentiation , biology , cell culture , u937 cell , cancer research , microbiology and biotechnology , immunology , medicine , stem cell , biochemistry , gene , genetics , coagulation
Tissue factor (TF) production is under strict control in mature monocytic cells. However, constitutive expression of TF can be found in myelomonocytic cells and in haematopoietic cells arrested at an early stage of differentiation. In this paper we show that TF expression is down‐regulated during the monocyte/granulocyte differentiation process, using the human monoblastic U‐937 and the acute promyelocytic leukaemia NB4 cell lines as models. Expression of TF mRNA, protein and procoagulant activity (PCA) was constitutively high in untreated cells. Exposure of U‐937 cells to 1 α,25‐dihydroxycholecalciferol (VitD 3 ) and all‐ trans retinoic acid (ATRA) resulted in down‐regulation of TF expression and PCA. In NB4 cells induction by ATRA, but not VitD 3 , resulted in the down‐regulation of TF expression and PCA. Consistent with this, induction of terminal differentiation, as confirmed by the expression of differentiation associated antigens and cell cycle arrest, was inversely correlated to TF expression in U‐937 and NB4 cells. Moreover, terminally differentiated U‐937 cells retained the capacity to respond to inflammatory mediators, i.e. lipopolysaccharide and interferon‐γ, by a rapid increase in TF expression. In conclusion, we show that not only ATRA but also VitD 3 is a potent suppressor of monocytic TF expression and thus might have potential clinical use for the treatment of coagulopathies.